Edition:
United States

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

2.94USD
15 Dec 2017
Change (% chg)

$0.01 (+0.34%)
Prev Close
$2.93
Open
$2.90
Day's High
$2.97
Day's Low
$2.85
Volume
387,495
Avg. Vol
524,122
52-wk High
$4.24
52-wk Low
$0.50

Select another date:

Thu, Dec 7 2017

BRIEF-Aveo Oncology Announces Clinical Updates To Tivozanib And Ficlatuzumab Programs

* AVEO ONCOLOGY ANNOUNCES CLINICAL UPDATES TO TIVOZANIB AND FICLATUZUMAB PROGRAMS

BRIEF-Aveo Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln

* AVEO PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING Source text: [http://bit.ly/2Bzw8T1] Further company coverage:

Ex-Aveo Pharmaceuticals CEO settles SEC fraud claims

Aveo Pharmaceuticals Inc's former chief executive has agreed to settle a lawsuit by the Securities and Exchange Commission claiming he misled investors about the biotech company's efforts to obtain regulatory approval for a drug to treat kidney cancer.

BRIEF-AVEO PHARMACEUTICALS REPORTS Q3 LOSS PER SHARE $0.22

* AVEO REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Aveo Pharmaceuticals- Tivo-3 study will continue as planned without modification

* Aveo Pharmaceuticals Inc - ‍announces completion of Tivo-3 study futility analysis with no changes to study protocol​

BRIEF-AVEO Oncology and EUSA Pharma announce TiNivo combination study opt-in

* Aveo Pharmaceuticals Inc - ‍EUSA Pharma has agreed to pay AVEO up to $388 million in future milestone payments and research and development funding​

BRIEF-Aveo Oncology announces Fotivda approved in the EU for the treatment of advanced renal cell carcinoma

* Aveo Oncology announces Fotivda® (tivozanib) approved in the European Union for the treatment of advanced renal cell carcinoma

BRIEF-Aveo Pharmaceuticals Inc Q2 loss per share $0.30

* Aveo reports second quarter 2017 financial results and provides business update

BRIEF-Aveo Oncology gets $14 mln from Hercules Credit Facility and at-the-market stock offerings

* Aveo Oncology announces $14m in aggregate gross proceeds from Hercules Credit Facility and at-the-market stock offerings

EU regulators greenlight U.S. biotech Aveo's kidney cancer drug

European regulators on Friday recommended the approval of Aveo Pharmaceuticals Inc's drug to treat kidney cancer, marking a big victory for the U.S. biotech that has faced a number of setbacks in bringing the drug to the market.

Select another date: